• Novanta Inc. reported its fourth-quarter and full-year 2025 results, with quarterly sales rising to US$258.35 million and net income reaching US$17.47 million, while issuing 2026 revenue guidance of US$1.03–US$1.05 billion that aligns closely with market expectations.
• Alongside record quarterly revenue, Novanta highlighted a very large acquisition capacity of about US$1.5 billion and a 25% surge in bookings, underscoring strong demand for its technologies in areas such as AI-driven robotics and minimally invasive surgery.
• We’ll now explore how this combination of record revenue and robust bookings reshapes Novanta’s existing investment narrative and future outlook.

The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 23 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.

Novanta Investment Narrative Recap

To own Novanta, you have to believe its niche in medical and industrial technology, especially robotics and advanced surgery, can support durable demand despite modest recent earnings and premium valuation. The latest results reinforce that story by pairing record quarterly revenue with strong bookings, but they do not materially change the near term tension between acquisition driven growth and the risk that organic momentum, margins and returns stay subdued.

The most relevant update here is Novanta’s 2026 revenue guidance of US$1.03 billion to US$1.05 billion, which closely tracks prior expectations and frames how investors assess the recent bookings surge as a potential bridge from today’s mid single digit organic growth to future performance. That guidance, alongside roughly US$1.5 billion of stated acquisition capacity, keeps the focus squarely on execution in M&A and manufacturing regionalization as the key short term swing factors.

But against this promising backdrop, investors should still be aware that exposure to trade disruptions and manufacturing relocation complexity could...

Novanta's narrative projects $1.1 billion revenue and $135.3 million earnings by 2028.

Uncover how Novanta's forecasts yield a $154.00 fair value, a 13% upside to its current price.

Exploring Other Perspectives

Three fair value estimates from the Simply Wall St Community range from about US$110 to US$160 per share, underscoring how differently people assess Novanta today. You can weigh those views against the recent earnings and guidance, which keep acquisition execution and margin recovery at the center of the story for the company’s longer term performance.

Explore 3 other fair value estimates on Novanta - why the stock might be worth as much as 17% more than the current price!

Reach Your Own Conclusion

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Novanta research is our analysis highlighting 1 key reward and 1 important warning sign that could impact your investment decision.
• Our free Novanta research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Novanta's overall financial health at a glance.

Ready To Venture Into Other Investment Styles?

These stocks are moving-our analysis flagged them today. Act fast before the price catches up:

• Explore 23 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.
• We've uncovered the 15 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.
• Uncover the next big thing with 30 elite penny stocks that balance risk and reward.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.